Eisai, Daiichi Sankyo In U.S. Battle Over Aricept Generics
This article was originally published in PharmAsia News
Major Japanese drugmakers Daiichi Sankyo and Eisai are engaged in a battle in the United States over a new market for both companies generic drugs. Daiichi Sankyo's Indian unit, Ranbaxy Laboratories, has six-month U.S. exclusivity for a generic version of Eisai's blockbuster Aricept (donepezil) for treating Alzheimer's disease. To counter that competition, Eisai granted U.S.-based Pfizer's Greenstone unit the right to sell its own generic in exchange for royalty payments. That portion of projected Aricept sales is expected to reach $200 million before late May when Ranbaxy's exclusivity expires. (Click here for more - a subscription may be required
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.